» Articles » PMID: 33071973

Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review

Overview
Specialty Endocrinology
Date 2020 Oct 19
PMID 33071973
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Silent corticotroph adenoma (SCA) is clinically non-functional pituitary adenoma with expression of corticotropin or Tpit. To further understand the characteristics of this rare type of SCA transforming to a functional SCA, we retrospectively reviewed SCAs that converted to typical Cushing's syndrome at a tertiary medical center and the relevant literature. Patients were identified based on the diagnosis of pituitary adenoma without symptoms of hypercortisolism at the initial visit with positive Immunohistochemical (IHC) staining for corticotropin or Tpit after surgery and subsequent transformation to functional SCAs during the follow-up period from March 1990 to January 2020 at Peking Union Medical College Hospital and in the literature. The characteristics of the clinical manifestations, biochemical results, imaging findings, pathology findings and outcome were analyzed. Altogether, 16 patients were included in the study with an average age of 42.0 ± 12.48 (18-65) years at the first visit. Females were slightly predominant (F:M = 1.3:1). The median time of conversion from the nonfunctional to the functional type was 30 (13.0, 68.3) months. Once a functional SCA developed, the adrenocorticotropic hormone (ACTH) level and 24-h urine free cortisol were increased 3.8- (2.6, 12.9) and 5.3- (2.6, 19.3) fold, respectively, above the normal range. Approximately 50% of the patients had macrocystic changes on pituitary MRI. All 16 patients experienced 1-5 surgeries with a median of 2.5 (2.0, 4.0) surgeries. The proportion of patients with Ki-67 ≥ 3% increased from 22.2% (2/9) at the beginning to 50% (7/14) at the time of functional SCA diagnosis. Thirteen patients received radiotherapy, and 4 patients (30.8%) achieved remission. Four patients with refractory functional SCAs received temozolomide treatment with the normalization of cortisol in 4 cases and reduced tumor volume in 3 cases. In this study, all cases that transformed to functional SCAs were macroadenomas. Hypercortisolism was more severe in functional SCA patients. The tumors tended to have frequent recurrence and were highly invasive. Temozolomide could be a promising treatment for refractory functional SCA cases. Long-term follow-up is needed for nonfunctional SCAs since some cases have the potential to transform to clinical Cushing's syndrome.

Citing Articles

Splicing diversity enhances the molecular classification of pituitary neuroendocrine tumors.

Huang Y, Guo J, Han X, Zhao Y, Li X, Xing P Nat Commun. 2025; 16(1):1552.

PMID: 39934142 PMC: 11814191. DOI: 10.1038/s41467-025-56821-x.


A rare case of double pituitary prolactinomas: the diagnostic application of intraoperative ultrasonography and DNA methylation markers.

Reese J, Zervos T, Rock J, Tabbarah A, Noushmehr H, Herrgott G Arch Endocrinol Metab. 2025; 68(Spec Issue):e230506.

PMID: 39876960 PMC: 11771751. DOI: 10.20945/2359-4292-2023-0506.


Characteristics and treatment of a silent somatotroph tumor that had transformed to a functional type: a case report and literature review.

Li Z, Wu Y, Sun J, Wang R, Bao X Gland Surg. 2024; 13(7):1322-1330.

PMID: 39175709 PMC: 11336798. DOI: 10.21037/gs-24-79.


Phenotype Transformation of PitNETs.

Li Z, Wu Y, He G, Wang R, Bao X Cancers (Basel). 2024; 16(9).

PMID: 38730682 PMC: 11083144. DOI: 10.3390/cancers16091731.


The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.

Kober P, Rusetska N, Mossakowska B, Maksymowicz M, Pekul M, Zielinski G Front Endocrinol (Lausanne). 2023; 14:1124646.

PMID: 37065760 PMC: 10090509. DOI: 10.3389/fendo.2023.1124646.


References
1.
Saeger W, Ludecke D, Buchfelder M, Fahlbusch R, Quabbe H, Petersenn S . Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007; 156(2):203-16. DOI: 10.1530/eje.1.02326. View

2.
Ben-Shlomo A, Cooper O . Silent corticotroph adenomas. Pituitary. 2018; 21(2):183-193. DOI: 10.1007/s11102-018-0864-8. View

3.
Tomita T, Gates E . Pituitary adenomas and granular cell tumors. Incidence, cell type, and location of tumor in 100 pituitary glands at autopsy. Am J Clin Pathol. 1999; 111(6):817-25. DOI: 10.1093/ajcp/111.6.817. View

4.
Scheithauer B, Jaap A, Horvath E, Kovacs K, Lloyd R, Meyer F . Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery. 2000; 47(3):723-9; discussion 729-30. DOI: 10.1097/00006123-200009000-00039. View

5.
Matsuno A, Okazaki R, Oki Y, Nagashima T . Secretion of high-molecular-weight adrenocorticotropic hormone from a pituitary adenoma in a patient without Cushing stigmata. Case report. J Neurosurg. 2004; 101(5):874-7. DOI: 10.3171/jns.2004.101.5.0874. View